SCHEMBL2005189

SCHEMBL2005189

FC(F)(F)Oc1ccc(Nc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.64
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
PDE10A Q9Y233 5/20 0.60
KDR P35968 1/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MAPT P10636 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CSNK1A1 P48729 1/20 0.48
CSNK1D P48730 1/20 0.48
DDX3X O00571 1/20 0.47
ABCB1 P08183 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21278775 0.82 MTOR (0.45) MTORMEN1KMT2APDE10AKDR
SCHEMBL1998129 0.81 MTOR (0.67) MTORMEN1KMT2APDE10ANPC1
SCHEMBL1163865 0.81 KDM4E (0.67) MEN1KMT2APDE10AKDRNPC1
SCHEMBL25283222 0.80 CSNK1D (0.51) MTORMEN1KMT2APDE10AKDR
SCHEMBL5361414 0.80 KDR (0.49) MTORMEN1KMT2APDE10AKDR
SCHEMBL20685279 0.80 TYK2 (0.45) MTORMEN1KMT2APDE10ANPC1
SCHEMBL20685294 0.80 CSNK1D (0.57) MTORPDE10ACSNK1A1CSNK1D
SCHEMBL1996591 0.79 MEN1 (0.71) MTORMEN1KMT2APDE10ANPC1
SCHEMBL20685327 0.79 POLB (0.56) MEN1KMT2APDE10AKDRNPC1
SCHEMBL20685402 0.79 MTOR (0.42) MTORMEN1KMT2APDE10AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US claimed
EP-3105210-B1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS Bayer Pharma AG (DE) 2019-01-30 EP disclosed
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US disclosed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels KCNN2, KCNN1, KCNN3 MTOR 1082/4885MEN1 2186/4885KMT2A 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.